Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center.
Jiangning Gu,Zhiwei Xu,Yang Ma,Hao Chen,Di Wang,Xiaxing Deng,Dongfeng Cheng,Junjie Xie,Jiabin Jin,Xi Zhan,Yuan Shi,Yusheng Shi,Youwei Zhu,Baiyong Shen,Chenghong Peng
DOI: https://doi.org/10.21037/jgo.2020.03.02
2020-01-01
Journal of Gastrointestinal Oncology
Abstract:BACKGROUND:The significance of surgical resection in the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) is currently unclear. This study aimed to summarize and clarify the experience of surgical treatment of M1 PDAC in our center and evaluate whether it may offer benefits to some metastatic PDAC patients.
METHODS:We analyzed the data of the patients with M1 PDAC who underwent synchronous tumor resection between 2003 and 2014 at Ruijin Hospital. Simultaneously, clinical data for M1 PDAC patients who underwent palliative bypass or exploratory laparotomy only was also collected during the same period as control. Every patient was followed up at least 3 years after hospitalization. The follow-up endpoint was December 31, 2017.
RESULTS:A total of 36 patients underwent synchronous tumor resection; of them, 7 received postoperative adjuvant chemotherapy. Their 1-, 2-, and 3-year survival rates were 27.3%, 21.2%, and 7.1%, respectively, and the overall survival was 7.9 months. The overall survival of the palliative bypass and exploratory laparotomy groups was only 4 and 3.7 months, respectively (P<0.05).
CONCLUSIONS:It is unclear whether synchronous tumor resection can benefit M1 PDAC patients due to tumor heterogeneity and differences in tumor burden. However, our current experience indicated that synchronous tumor resection can be safely performed and might be appropriate for some highly selected patients due to the relatively longer survival time. Combined (neo)adjuvant chemotherapy would further prolong overall survival in these patients.